The Oslo-based radiopharmaceutical company has raised NOK 148.5 million in a private placement and retail offering to complete its Phase 2 ovarian cancer trial and prepare for Phase 3.

The World Health Organization (WHO) has identified SynAct Pharma’s resomelagon as one of six dengue drug candidates with evidence supporting further clinical development, according to a review published in The Lancet Microbe.

Elicera Therapeutics has received approval from the Swedish Medical Products Agency (Läkemedelsverket) to move its CARMA study of the CAR T-cell therapy ELC-301 in B-cell lymphoma into Phase IIa.

The company is to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company, provisionally named ‘Mölnlycke Surgical’, while Wound Care and Antiseptics continue as Mölnlycke.

RaySearch Laboratories and US-based Accuray have entered a definitive agreement to expand their collaboration on online adaptive radiation therapy, with Accuray committing to purchase RayStation software licences worth USD 8 million.

Glycorex Transplantation has agreed a distribution deal with Grupo VIDA for its Glycosorb ABO technology in Brazil, as part of the Swedish medtech company’s continued market expansion.

Swedish biotech company MucoShield is developing a locally administered, fast-acting treatment to protect the oral mucosa during chemotherapy and prevent severe chemotherapy-induced oral mucositis, one of the most painful and debilitating side effects of cancer treatment.

BioArctic’s Alzheimer’s drug Leqembi is now available at a private clinic in Stockholm, where the first patient in Sweden to receive the drug outside a clinical trial started treatment on September 22. This comes five months after the NT Council advised Sweden’s regions against using it.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Pepaxti (melflufen) be extended to earlier lines of multiple myeloma treatment, a move that would significantly widen the drug’s eligible patient population.

Patients who had high-risk polyps removed and waited five years for their first follow-up colonoscopy had a colorectal cancer risk similar to those examined after three years, according to two studies in the New England Journal of Medicine involving Karolinska Institutet (KI) researchers.

Professor Signe Sørensen Torekov and Assistant Professor Lærke Smidt Gasbjerg, both at the University of Copenhagen, are this year’s recipients of the obesity research prizes awarded by the Danish Association for the Study of Obesity (DASO) and the Novo Nordisk Foundation.

David Ginty (Harvard Medical School/Howard Hughes Medical Institute) and Patrik Ernfors (Karolinska Institutet) have been awarded The Brain Prize 2026, the world’s largest research prize in neuroscience, for work that has redrawn the cellular map of how the nervous system senses touch and pain.